Our ultimate aim is to improve the living conditions of those in need. We often do so by helping our partner organizations become more effective or by directly advancing a topic. We evaluate our impact by looking at what we achieved within the organization, as well as the ultimate effect on beneficiaries.
For example, in recent work with one of our global partners, we supported preparations for the successful launch of a novel meningitis vaccine developed specifically for sub-Saharan Africa. Working with the Bill & Melinda Gates Foundation and the Meningitis Vaccine Project (MVP), BCG conducted a critical-path analysis to assess key risks that might jeopardize the anticipated vaccine launch.
Together with its partners, MVP addressed these risk factors, and in December 2010, 14 million doses of the vaccine were introduced successfully in Burkina Faso, enabling 80 percent of the population to be vaccinated in just four months.
The introduction of this vaccine across sub-Saharan Africa has the potential to avert 140,000 deaths, 300,000 disabilities, and $120 million in treatment costs over the next ten years.